[go: up one dir, main page]

WO2008073304A3 - Cancer treatment methods - Google Patents

Cancer treatment methods Download PDF

Info

Publication number
WO2008073304A3
WO2008073304A3 PCT/US2007/025095 US2007025095W WO2008073304A3 WO 2008073304 A3 WO2008073304 A3 WO 2008073304A3 US 2007025095 W US2007025095 W US 2007025095W WO 2008073304 A3 WO2008073304 A3 WO 2008073304A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer treatment
treatment methods
methods
treating cancer
piperidinecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/025095
Other languages
French (fr)
Other versions
WO2008073304A2 (en
WO2008073304A9 (en
Inventor
Daniel C Adelman
Ute Hoch
Duncan Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viracta Therapeutics Inc
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of WO2008073304A2 publication Critical patent/WO2008073304A2/en
Publication of WO2008073304A3 publication Critical patent/WO2008073304A3/en
Publication of WO2008073304A9 publication Critical patent/WO2008073304A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating cancer comprising use of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide are provided. Also provided are methods of treating cancer using the compound in combination with other therapies.
PCT/US2007/025095 2006-12-08 2007-12-07 Cancer treatment methods Ceased WO2008073304A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US87377606P 2006-12-08 2006-12-08
US60/873,776 2006-12-08
US87949407P 2007-01-08 2007-01-08
US60/879,494 2007-01-08
US92343207P 2007-04-13 2007-04-13
US60/923,432 2007-04-13
US97151307P 2007-09-11 2007-09-11
US60/971,513 2007-09-11
US99997907P 2007-10-22 2007-10-22
US60/999,979 2007-10-22

Publications (3)

Publication Number Publication Date
WO2008073304A2 WO2008073304A2 (en) 2008-06-19
WO2008073304A3 true WO2008073304A3 (en) 2008-08-07
WO2008073304A9 WO2008073304A9 (en) 2008-09-18

Family

ID=39512270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025095 Ceased WO2008073304A2 (en) 2006-12-08 2007-12-07 Cancer treatment methods

Country Status (1)

Country Link
WO (1) WO2008073304A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078492A1 (en) * 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
WO2006101846A1 (en) * 2005-03-16 2006-09-28 Aventis Pharmaceuticals Inc. Dosing regimen of flavopiridol for treating cancer in particular cll

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
WO2006101846A1 (en) * 2005-03-16 2006-09-28 Aventis Pharmaceuticals Inc. Dosing regimen of flavopiridol for treating cancer in particular cll

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLAGDEN ET AL.: "Drugging cell cycle kinases in cancer therapy", CURRENT DRUG TARGETS, vol. 6, 2005, pages 325 - 335, XP009075380, DOI: doi:10.2174/1389450053765824 *
FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH: "Oncology tools, Dose Calculator", Retrieved from the Internet <URL:http://www.fda.gov/cder/cancer/animalframe.htm> *

Also Published As

Publication number Publication date
WO2008073304A2 (en) 2008-06-19
WO2008073304A9 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
PT2947072T (en) 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
IL199673A0 (en) 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2008109697A3 (en) Ppar active compounds
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
AU2006343359A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
PH12012500168A1 (en) Crystalline solvates and complexes of (is)-1,5-anhydro-l-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
WO2009105513A8 (en) Novel compounds and methods for therapy
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
IL200403A0 (en) Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
WO2008112647A3 (en) Nitroxide radical as a treatment for neurodegeneration
WO2009048980A3 (en) Emp2 antibodies and their therapeutic uses
PL2410047T3 (en) Oxidoreductase and its use for the reduction of secodione derivatives
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008066775A3 (en) Compositions and methods to reduce fat and retract skin
WO2007059226A3 (en) Photoactivatable antimicrobial agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862643

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07862643

Country of ref document: EP

Kind code of ref document: A2